Stockscreener 앱 받기
0.388
0.26%
-0.001
시간 외 거래:
2.66
2.272
+585.57%
전일 마감가:
$0.389
열려 있는:
$0.37
하루 거래량:
302.17K
Relative Volume:
0.29
시가총액:
$12.24M
수익:
-
순이익/손실:
$-45.68M
주가수익비율:
-0.0265
EPS:
-14.6193
순현금흐름:
$-12.91M
1주 성능:
-4.13%
1개월 성능:
-6.39%
6개월 성능:
-47.10%
1년 성능:
-83.63%
1일 변동 폭
$0.37
$0.39
1주일 범위
$0.3506
$0.409
52주 변동 폭
$0.3506
$3.85
Gt Biopharma Inc Stock (GTBP) Company Profile
명칭
Gt Biopharma Inc
전화
(800) 304-9888
주소
505 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP vs MOBBW, GOODO, PSNYW, SHMD, DWLD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
1.82 | 2.55B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
19.85 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.70 | 356.14M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
5.81 | 315.27M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
46.21 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-02 | 개시 | ROTH MKM | Buy |
| 2021-05-24 | 개시 | H.C. Wainwright | Buy |
| 2021-04-13 | 개시 | B. Riley Securities | Buy |
| 2021-03-17 | 개시 | ROTH Capital | Buy |
Gt Biopharma Inc 주식(GTBP)의 최신 뉴스
GTBP Forecast, Price Target & Analyst Ratings | GT BIOPHARMA INC (NASDAQ:GTBP) - ChartMill
GTBP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
GT Biopharma enters agreement with University of Minnesota for phase 1 trial - Investing.com Australia
GT Biopharma enters agreement with University of Minnesota for phase 1 trial By Investing.com - Investing.com South Africa
GT Biopharma Advances GTB-5550 via University Trial Pact - TipRanks
GT Biopharma (NASDAQ: GTBP) backs $3.8M GTB-5550 cancer trial pact - Stock Titan
GT Biopharma, Inc. Enters into Investigator Initiated Clinical Trial Agreement with Regents of the University of Minnesota - marketscreener.com
GTBP SEC FilingsGt Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
VIX Spike: Will GT Biopharma Inc benefit from government policyTrade Risk Assessment & Stepwise Swing Trade Plans - baoquankhu1.vn
Analyst Calls: Will GT Biopharma Inc benefit from government policyWeekly Trend Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
Recap Report: Can GT Biopharma Inc outperform under higher oil prices2026 EndofMonth & Verified Swing Trading Watchlist - baoquankhu1.vn
If You Invested $1,000 in Gt Biopharma Inc (GTBP) - Stock Titan
GT Biopharma (GTBP) Projected to Post Quarterly Earnings on Wednesday - Defense World
If You Invested $1,000 in Purple Biotech Ltd (PPBT) - Stock Titan
GTBP Stock Chart | GT BIOPHARMA INC (NASDAQ:GTBP) - ChartMill
Published on: 2026-03-21 08:49:55 - baoquankhu1.vn
Panic Selling: Can GT Biopharma Inc outperform under higher oil prices2026 Rallies & Technical Entry and Exit Alerts - baoquankhu1.vn
GT Biopharma (GTBP) upgraded to buy: Here's what you should know - MSN
GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
GT Biopharma (GTBP) Raised to Buy: Key Information You Need - Bitget
GT Biopharma (GTBP) forms 'hammer chart pattern': Time for bottom fishing? - MSN
GT Biopharma (GTBP) Develops 'Hammer Chart Pattern': Is It an Opportunity to Buy at the Bottom? - Bitget
GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
Should I buy GT Biopharma (GTBP) - Zacks Investment Research
GT Biopharma to Participate in the 38th Annual Roth Conference - Bitget
GT Biopharma, Inc. Files Restated Q3 2025 10-Q/A Due to Greenshoe Rights Liability Accounting Error - Minichart
GT Biopharma, Inc. 2025 Q2 Amended Quarterly Report (10-Q/A): Restatement Due to Greenshoe Rights Liability, Financial Statements & SEC Compliance - Minichart
Will GT Biopharma Inc. (OXIA) stock beat value stocksWeekly Profit Summary & Technical Pattern Based Buy Signals - Naître et grandir
Stock Market Recap: Can GT Biopharma Inc outperform under higher oil pricesJuly 2025 Momentum & Consistent Return Investment Signals - baoquankhu1.vn
GT Biopharma (NASDAQ: GTBP) restates Q2 2025 and warns on going concern - Stock Titan
[10-Q/A] GT Biopharma, Inc. Amended Quarterly Earnings Report | GTBP SEC FilingForm 10-Q/A - Stock Titan
GTBP Earnings History & Surprises | EPS & Revenue Results | GT BIOPHARMA INC (NASDAQ:GTBP) - ChartMill
GTBP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GT Biopharma (GTBP) Gets FDA Green Light to Test New Cancer-Fighting Tech in Humans - Barchart
GTBPForm 8-KCurrent report - Revista ADVFN
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
GT Biopharma to restate 2025 financials after error in Greenshoe Rights accounting - Investing.com UK
GT Biopharma to restate 2025 financials after error in Greenshoe Rights accounting By Investing.com - Investing.com South Africa
GTBP: Net loss increased to $28.4M in 2025, with cash runway projected through Q4 2026 - TradingView
GT Biopharma 2025 10‑K: $0 Revenue, $(6.68) EPS, $28.35M net loss - TradingView
GT Biopharma (NASDAQ: GTBP) details cash strain, losses and $20M equity line - Stock Titan
GTBP: Net loss rose to $28.4M in 2025, with ongoing liquidity risks and urgent need for new capital - TradingView
Restatement of 2025 quarters at GT Biopharma (NASDAQ: GTBP) - Stock Titan
GT Biopharma Reports Full Year 2025 Financial Results - marketscreener.com
Cancer trial firm GT Biopharma says $9M cash funds work into late 2026 - Stock Titan
GT Biopharma, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
Should I Buy GTBP? GTBP 2026 AnalysisIntellectia AI™ - Intellectia AI
Can GT Biopharma Inc. outperform under higher oil pricesJuly 2025 Snapshot & Verified Swing Trading Watchlist - mfd.ru
Why GT Biopharma Inc. (OXIA) stock could be top winnerPortfolio Growth Summary & Technical Analysis for Trade Confirmation - mfd.ru
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference - The Manila Times
Immuno-oncology GT Biopharma to detail TriKE platform for Toronto investors - Stock Titan
Gt Biopharma Inc (GTBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):